Hong Jae Chon, Director of Cancer Center, CHA Bundang Medical Center, shared a post on X:
“Our new study with David James Pinato has recently been published in Journal of Hepatology.!
Can primary refractoriness to Ate/Bev in HCC be predicted before treatment?
Among patients with low IFN-γ signature and high NLR, surrogate markers of a myeloid immunosuppressive phenotype, 74% were identified as primarily refractory to Ate/Bev.”
Title: A myeloid immunosuppressive phenotype defines primary refractoriness to atezolizumab Plus bevacizumab in hepatocellular caarcinoma.
Authors: Pasquale Lombardi, Erik Ramon-Gil, Rabial Raja, Leonardo Brunetti, Giulia Manfredi, Zhongguo Zhou, George Merces, Sarah Cappuyns, Claudia Fulgenzi, Antonio D’Alessio, Aria Torkpour, Ciro Celsa, Bernardo Stefanini, Hannah Yang, Fionnuala Crowley, Thomas Marron, Anwaar Saeed, Matthias Pinter, Bernhard Scheiner, Yi-Hsiang Huang, Pei-Chang Lee, Naoshi Nishida, Ryan Lin, Andrea Dalbeni, Caterina Vivaldi, Gianluca Masi, Natascha Rohlen, Johann von Felden, Ahmed Kaseb, Peter Galle, Masatoshi Kudo, Wei-Fan Hsu, Lorenza Rimassa, Alessandro Parisi, Robin Kelley, Hidenori Toyoda, Mario Pirisi, Falah Jabar, Mehrdad Rakaee, Giuseppe Cabibbo, Calogero Cammà, Fabio Piscaglia, Sohyun Hwang, Dong Jun Shin, Michael Li, Jeroen Dekervel, Nadia Guerra, Tim Meyer, Helen Reeves, Bertram Bengsch, Gennaro Daniele, Derek Mann, Hong Jae Chon, Jack Leslie, David Pinato
Read the Full Article on Journal of Hepatology.
More posts featuring Hong Jae Chon.
